DSM acquires Biopract to enter fast growing biogas market
Royal DSM N.V., the global Life Sciences and Materials Sciences
company headquartered in the Netherlands, today announces an
agreement to acquire Biopract GmbH, based in Berlin (Germany). The
acquisition of privately held Biopract will serve as an entry point
for DSM into the promising biogas market, which is showing 15-20%
growth per year.
The acquisition has been finalized. Parties agreed not to disclose
financial details of the acquisition. The impact of the acquisition
on DSM's net sales in 2009 and 2010 is not expected to be material.
Founded in 1992, Biopract's main focus has been on the
commercialization and extension of their Methaplus(TM) enzyme series
for the improvement of agricultural and industrial biogas production.
The company has a strong application and technology position in this
field.
Rob van Leen, Chief Innovation Officer of DSM said: "We are convinced
that biotechnology will contribute significantly to the sustainable
and efficient use of natural resources today and in the future. We
look forward to combining Biopract's expertise with ours to further
increase the efficiency and performance of biogas plants."
Biogas is produced by anaerobic fermentation of biodegradable
materials such as biomass, manure or sewage, green waste and energy
crops. It can be used to generate electricity and as a low-cost fuel
for any heating purpose. Biogas can also be upgraded to natural gas
quality.
Driven by climate change and alternative energy initiatives, the
market for production and optimization of biogas-related processes
will become significant in the coming years. The acquisition of
Biopract will accelerate DSM's growth in this market.
Biopract's activities will be integrated into DSM's biogas service
concept for optimizing the biotechnology of biogas plants. Based on a
thorough analysis of the production process, DSM offers agricultural
and industrial biogas plants tailor-made advice and a product mix to
improve the biotechnology process and to increase the performance of
the plant.
DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life
Sciences and Materials Sciences that contribute to the quality of
life. DSM's products and services are used globally in a wide range
of markets and applications, supporting a healthier, more sustainable
and more enjoyable way of life. End markets include human and animal
nutrition and health, personal care, pharmaceuticals, automotive,
coatings and paint, electrical and electronics, life protection and
housing. DSM has annual net sales of EUR 9.3 billion and employs some
23,500 people worldwide. The company is headquartered in the
Netherlands, with locations on five continents. DSM is listed on
Euronext Amsterdam. More information: www.dsm.com
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 tel. +31 (0) 45 5782864
5782017 fax +31 (0) 45 5782595
fax +31 (0) 45 e-mail
5740680 investor.relations@dsm.com
e-mail media.relations@dsm.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.